SU-9803

N/A

Report date: 2024/12/18 13:39:48
NME

Base Information

Drug NameSU-9803
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptors antagonistsVascular endothelial growth factor receptor antagonistsProtein-tyrosine kinases inhibitors
TargetsFibroblast growth factor receptorsProtein-tyrosine kinasesVascular endothelial growth factor receptor
Therapy Area/IndicationsGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSugen LlcThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSugen LlcThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsGlioma

Other Information

ATC CodeN/A
Related LinksN/A